Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis

Joshua C. Yelverton, Thomas W. Holmes, Christopher M. Johnson, Camilo Reyes Gelves, Stilianos E. Kountakis

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes. Methods: Retrospective review of collected data at a tertiary-referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group. Twenty-item Sino-Nasal Outcomes Test (SNOT-20) scores and Lund-Kennedy endoscopy scores were obtained for each patient. Scores were compared with and without montelukast using Wilcoxon signed rank test. The analysis was controlled for changes in other medications. Results: Fifty-two therapy lapses were identified in 50 patients. Twenty-seven patients had eosinophilic CRS with polyps (eCRSwNP), 8 had Samter's triad (ST), and 15 had allergic fungal sinusitis (AFS). Overall mean follow-up was 46.5 months. Overall, SNOT-20 scores and endoscopy scores were significantly lower with montelukast (p < 0.005 for both). On subgroup analysis, SNOT-20 scores were significantly improved for patients with eCRSwNP and AFS (p < 0.001 and p = 0.001, respectively). Endoscopy scores were significantly improved for patients with eCRSwNP (p = 0.044). Outcomes approached, but did not reach, significance for patients with ST (p = 0.123 for SNOT-20 and p = 0.146 for endoscopy). There was also significant improvements in patients with asthma. Conclusion: The addition of montelukast as postoperative therapy may be beneficial for patients with eCRSwNP and AFS.

Original languageEnglish (US)
Pages (from-to)243-247
Number of pages5
JournalInternational Forum of Allergy and Rhinology
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Leukotriene Receptors
montelukast
Endoscopy
Sinusitis
Asthma
Therapeutics
Nonparametric Statistics
Polyps
Nose

Keywords

  • Leukotriene receptor antagonist
  • Montelukast
  • Postoperative outcomes
  • Rhinosinusitis
  • Sinusitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Cite this

Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis. / Yelverton, Joshua C.; Holmes, Thomas W.; Johnson, Christopher M.; Gelves, Camilo Reyes; Kountakis, Stilianos E.

In: International Forum of Allergy and Rhinology, Vol. 6, No. 3, 01.03.2016, p. 243-247.

Research output: Contribution to journalArticle

Yelverton, Joshua C. ; Holmes, Thomas W. ; Johnson, Christopher M. ; Gelves, Camilo Reyes ; Kountakis, Stilianos E. / Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis. In: International Forum of Allergy and Rhinology. 2016 ; Vol. 6, No. 3. pp. 243-247.
@article{5a9f1da2f5ef4f1d83ba233c8d4bb438,
title = "Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis",
abstract = "Background: Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes. Methods: Retrospective review of collected data at a tertiary-referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group. Twenty-item Sino-Nasal Outcomes Test (SNOT-20) scores and Lund-Kennedy endoscopy scores were obtained for each patient. Scores were compared with and without montelukast using Wilcoxon signed rank test. The analysis was controlled for changes in other medications. Results: Fifty-two therapy lapses were identified in 50 patients. Twenty-seven patients had eosinophilic CRS with polyps (eCRSwNP), 8 had Samter's triad (ST), and 15 had allergic fungal sinusitis (AFS). Overall mean follow-up was 46.5 months. Overall, SNOT-20 scores and endoscopy scores were significantly lower with montelukast (p < 0.005 for both). On subgroup analysis, SNOT-20 scores were significantly improved for patients with eCRSwNP and AFS (p < 0.001 and p = 0.001, respectively). Endoscopy scores were significantly improved for patients with eCRSwNP (p = 0.044). Outcomes approached, but did not reach, significance for patients with ST (p = 0.123 for SNOT-20 and p = 0.146 for endoscopy). There was also significant improvements in patients with asthma. Conclusion: The addition of montelukast as postoperative therapy may be beneficial for patients with eCRSwNP and AFS.",
keywords = "Leukotriene receptor antagonist, Montelukast, Postoperative outcomes, Rhinosinusitis, Sinusitis",
author = "Yelverton, {Joshua C.} and Holmes, {Thomas W.} and Johnson, {Christopher M.} and Gelves, {Camilo Reyes} and Kountakis, {Stilianos E.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1002/alr.21649",
language = "English (US)",
volume = "6",
pages = "243--247",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effectiveness of leukotriene receptor antagonism in the postoperative management of chronic rhinosinusitis

AU - Yelverton, Joshua C.

AU - Holmes, Thomas W.

AU - Johnson, Christopher M.

AU - Gelves, Camilo Reyes

AU - Kountakis, Stilianos E.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes. Methods: Retrospective review of collected data at a tertiary-referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group. Twenty-item Sino-Nasal Outcomes Test (SNOT-20) scores and Lund-Kennedy endoscopy scores were obtained for each patient. Scores were compared with and without montelukast using Wilcoxon signed rank test. The analysis was controlled for changes in other medications. Results: Fifty-two therapy lapses were identified in 50 patients. Twenty-seven patients had eosinophilic CRS with polyps (eCRSwNP), 8 had Samter's triad (ST), and 15 had allergic fungal sinusitis (AFS). Overall mean follow-up was 46.5 months. Overall, SNOT-20 scores and endoscopy scores were significantly lower with montelukast (p < 0.005 for both). On subgroup analysis, SNOT-20 scores were significantly improved for patients with eCRSwNP and AFS (p < 0.001 and p = 0.001, respectively). Endoscopy scores were significantly improved for patients with eCRSwNP (p = 0.044). Outcomes approached, but did not reach, significance for patients with ST (p = 0.123 for SNOT-20 and p = 0.146 for endoscopy). There was also significant improvements in patients with asthma. Conclusion: The addition of montelukast as postoperative therapy may be beneficial for patients with eCRSwNP and AFS.

AB - Background: Montelukast is used in the treatment of allergic rhinitis and asthma. It has been used as adjuvant therapy in patients with chronic rhinosinusitis (CRS), but its effectiveness has not been evaluated. This study evaluates the efficacy of adjuvant leukotriene receptor antagonism in CRS and subtypes. Methods: Retrospective review of collected data at a tertiary-referral institution. We identified all patients who were prescribed montelukast postoperatively and had a lapse in therapy for at least 1 month (n = 50), so that the patients themselves serve as their own control group. Twenty-item Sino-Nasal Outcomes Test (SNOT-20) scores and Lund-Kennedy endoscopy scores were obtained for each patient. Scores were compared with and without montelukast using Wilcoxon signed rank test. The analysis was controlled for changes in other medications. Results: Fifty-two therapy lapses were identified in 50 patients. Twenty-seven patients had eosinophilic CRS with polyps (eCRSwNP), 8 had Samter's triad (ST), and 15 had allergic fungal sinusitis (AFS). Overall mean follow-up was 46.5 months. Overall, SNOT-20 scores and endoscopy scores were significantly lower with montelukast (p < 0.005 for both). On subgroup analysis, SNOT-20 scores were significantly improved for patients with eCRSwNP and AFS (p < 0.001 and p = 0.001, respectively). Endoscopy scores were significantly improved for patients with eCRSwNP (p = 0.044). Outcomes approached, but did not reach, significance for patients with ST (p = 0.123 for SNOT-20 and p = 0.146 for endoscopy). There was also significant improvements in patients with asthma. Conclusion: The addition of montelukast as postoperative therapy may be beneficial for patients with eCRSwNP and AFS.

KW - Leukotriene receptor antagonist

KW - Montelukast

KW - Postoperative outcomes

KW - Rhinosinusitis

KW - Sinusitis

UR - http://www.scopus.com/inward/record.url?scp=84960087838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960087838&partnerID=8YFLogxK

U2 - 10.1002/alr.21649

DO - 10.1002/alr.21649

M3 - Article

C2 - 26834076

AN - SCOPUS:84960087838

VL - 6

SP - 243

EP - 247

JO - International Forum of Allergy and Rhinology

JF - International Forum of Allergy and Rhinology

SN - 2042-6976

IS - 3

ER -